prostate cancer

DESCRIPTION

Even though Prostate Cancer (PCa) remains the most frequently diagnosed cancer type in men (estimated to be the fifth leading cause of cancer related deaths in men worldwide), death rates for prostate cancer have been decreasing in many countries. In surgical treatment, incomplete resection of PCa and understaging of possible undetected metastases may lead to disease recurrence and consequently poor patient outcome. Curative options are indicated. One of these curative options is surgical removal of all cancerous tissue. Depending on the extent of the disease, surgery may be combined with Adjuvant Radiotherapy, hormone therapy and chemotherapy. To increase the chance of accurate staging and subsequently complete removal of all cancerous tissue, prostate specific membrane antigen (PSMA) targeting agents may provide the surgeon an aid for the intraoperative detection and removal of PCa lesions.

Sources: NIH.gov, ACS journals

Disclaimer

Image used with permission of Prof. Michael Hofman, Peter MacCallum Cancer Centre, Melbourne, Australia. Series of patients who received LuPSMA therapy after other treatments stopped working. In each patient, the extent of tumor spread before and after treatment is visualized with clarity using PSMA PET. These patients experienced improved quality of life, including reduction of pain correlated with marked reduction of prostate specific antigen (PSA), a blood tumor marker.

APPROVED TREATMENTS

¹⁷⁷Lu-Vipivotide tetraxetan (Pluvicto™) (metastasized castrate resistant prostate cancer (mCRPC)

¹⁶⁶Ho-Chitosan (Brachytherapy)

²²³Ra-Radium Dichloride (prostate cancer that has spread to the bones)

IN DEVELOPMENT

²²⁵Ac-PSMA-617

²²⁵Ac-FPI-2265

¹³¹I-RPS-001

¹⁷⁷Lu-CTT-1403

¹⁷⁷Lu-DOTAZOL

¹⁷⁷Lu-EB-PSMA-617

¹⁷⁷Lu-PNT2002

¹⁷⁷Lu-PSMA-R2

¹⁷⁷Lu-Rosopatamab

²²⁵Ac-Rosopatamab

¹⁷⁷Lu-rhPSMA-10.1

¹⁷⁷Lu-RM2

STATISTICS

View statistics

PATIENT ASSOCIATIONS

Europe: ANAMACap (FRA), APCLP (FRA), CERHOM – Association Cancers de l’homme (FRA), Movember Europe (GBR), Prostate Cancer UK (GBR), The prostate cancer association PROPA (DNK), EuropaUomo (EU), Wij Ook (BEL)

North America: Malecare Cancer Support (USA),  PCaAware (USA), PCaI-Prostate Cancer International (USA), Prostate Cancer Foundation (USA), Prostate Cancer Foundation Canada (CAD), The California Prostate Cancer Coalition (USA), Veterans Prostate Cancer Awareness (USA), YourProstateCancer.Help (USA), ZERO – The End of Prostate Cancer (USA)

Asia & Asia-Pacific: APC – Australian Prostate Centre (AUS), Prostate Cancer Foundation Australia (AUS), The Prostate Zone (AUS)

Worldwide:US-TOO!

CLINICAL TRIALS*

Prostate cancer ¹⁷⁷Lu based clinical trials

Prostate cancer ²²⁵Ac based clinical trials

Prostate cancer ²²³Ra based clinical trials

Prostate cancer ²¹²Pb based clinical trials

*non-exhaustive list

ABOUT PROSTATE CANCER

Prostate Cancer – Cancer.Net

Prostate Cancer information and overview – American Cancer Society

Prostate Cancer – Patient version – National Cancer Institute NIH